CA2500368A1
(en)
*
|
2002-10-04 |
2004-04-22 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Inhibition of src for treatment of reperfusion injury related to revascularization
|
TW200423938A
(en)
*
|
2003-02-21 |
2004-11-16 |
Wyeth Corp |
4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
|
WO2005046693A1
(en)
|
2003-11-06 |
2005-05-26 |
Wyeth |
4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
|
FR2862301B1
(fr)
*
|
2003-11-17 |
2007-12-21 |
Aventis Pharma Sa |
Nouveau procede de preparation de quinoleines 3-fluorees
|
TW200529846A
(en)
*
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
SI1802581T1
(sl)
*
|
2004-10-22 |
2008-08-31 |
Wyeth Corp |
4((2,4-dikloro-5-metoksifenil)amino)-6-alkoksi-7-etinil-3- kinolinkarbonitrili za zdravljenje ishemiäśne poĺ kodbe
|
RU2405566C2
(ru)
|
2005-02-03 |
2010-12-10 |
Дзе Дженерал Хоспитал Корпорейшн |
Способ лечения рака, устойчивого к гефитинибу
|
JP2008540656A
(ja)
*
|
2005-05-18 |
2008-11-20 |
ワイス |
Tpl2キナーゼの3−シアノキノリン阻害物質ならびにそれを製造および使用する方法
|
KR20140036336A
(ko)
|
2005-06-17 |
2014-03-25 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Src 키나제 억제제에 의한 골용해성 병변의 억제
|
MX2008000384A
(es)
|
2005-07-01 |
2008-03-07 |
Wyeth Corp |
Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metox i-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion.
|
PE20070763A1
(es)
|
2005-11-04 |
2007-08-08 |
Wyeth Corp |
COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
|
TW200808728A
(en)
*
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
US20080119463A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Wyeth |
4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
|
WO2008060283A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Wyeth |
4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
|
EP2478905B1
(en)
*
|
2007-06-01 |
2014-05-14 |
Wyeth LLC |
Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
CN101602687A
(zh)
*
|
2008-06-13 |
2009-12-16 |
上海特化医药科技有限公司 |
6-硝基苯乙酮类化合物、其制备方法及用途
|
MX365008B
(es)
|
2008-06-17 |
2019-05-20 |
Wyeth Llc |
Combinaciones antineoplasticas que contienen hki-272 y vinorelbina.
|
JP5681108B2
(ja)
*
|
2008-08-04 |
2015-03-04 |
ワイス・エルエルシー |
4−アニリノ−3−シアノキノリンとカペシタビンの抗新生物薬の組合せ
|
WO2010030835A2
(en)
*
|
2008-09-11 |
2010-03-18 |
Wyeth Llc |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
CN101723854A
(zh)
|
2008-10-24 |
2010-06-09 |
上海特化医药科技有限公司 |
6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
|
ES2561495T3
(es)
|
2009-04-06 |
2016-02-26 |
Wyeth Llc |
Régimen de tratamiento que utiliza neratinib contra cáncer de mama
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
ES2639407T3
(es)
|
2010-06-09 |
2017-10-26 |
Tianjin Hemay Oncology Pharmaceutical Co., Ltd. |
Derivados de cianoquinolina
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
WO2012080260A1
(en)
|
2010-12-13 |
2012-06-21 |
Novartis Ag |
Dimeric iap inhibitors
|
SG192769A1
(en)
|
2011-03-04 |
2013-09-30 |
Glaxosmithkline Ip No 2 Ltd |
Amino-quinolines as kinase inhibitors
|
JP2014520858A
(ja)
|
2011-07-13 |
2014-08-25 |
ノバルティス アーゲー |
タンキラーゼ阻害剤として用いるための新規な2−ピペリジン−1−イル−アセトアミド化合物
|
ES2548513T3
(es)
|
2011-07-13 |
2015-10-19 |
Novartis Ag |
Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa
|
CN103814032A
(zh)
|
2011-07-13 |
2014-05-21 |
诺华股份有限公司 |
用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
US10023862B2
(en)
|
2012-01-09 |
2018-07-17 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat beta-catenin-related diseases
|
TW201425307A
(zh)
|
2012-09-13 |
2014-07-01 |
Glaxosmithkline Llc |
作為激酶抑制劑之胺基-喹啉類
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
CN103804353A
(zh)
*
|
2012-11-01 |
2014-05-21 |
常辉 |
一类治疗精神分裂症的化合物及其用途
|
WO2014127214A1
(en)
|
2013-02-15 |
2014-08-21 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
KR102279999B1
(ko)
|
2013-02-19 |
2021-07-22 |
노파르티스 아게 |
선택적 에스트로겐 수용체 분해제로서의 벤조티오펜 유도체 및 그의 조성물
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
US9353123B2
(en)
|
2013-02-20 |
2016-05-31 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
BR112015019624A2
(pt)
|
2013-02-21 |
2017-07-18 |
Glaxosmithkline Ip Dev Ltd |
quinazolinas como inibidores de quinase
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
NZ710929A
(en)
|
2013-03-15 |
2018-02-23 |
Novartis Ag |
Antibody drug conjugates
|
WO2015066482A1
(en)
|
2013-11-01 |
2015-05-07 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
EP3094627B1
(en)
|
2014-01-17 |
2018-08-22 |
Novartis AG |
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
EP2980088A1
(en)
|
2014-07-28 |
2016-02-03 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted isothiazoles
|
WO2015123758A1
(en)
*
|
2014-02-20 |
2015-08-27 |
Apotex Inc. |
Bosutinib forms and preparation methods thereof
|
WO2015149727A1
(en)
|
2014-04-02 |
2015-10-08 |
Zentiva, K.S. |
Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
EP3180360A1
(en)
|
2014-08-12 |
2017-06-21 |
Novartis AG |
Anti-cdh6 antibody drug conjugates
|
AU2015314756A1
(en)
|
2014-09-13 |
2017-03-16 |
Novartis Ag |
Combination therapies of alk inhibitors
|
AU2015327868A1
(en)
|
2014-10-03 |
2017-04-20 |
Novartis Ag |
Combination therapies
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
CN104311485B
(zh)
*
|
2014-10-13 |
2016-08-24 |
烟台市华文欣欣医药科技有限公司 |
一种治疗白血病的药物博舒替尼的制备方法
|
PE20170912A1
(es)
|
2014-11-14 |
2017-07-12 |
Novartis Ag |
Conjugados de anticuerpo-farmaco
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
CN107530430A
(zh)
|
2015-01-13 |
2018-01-02 |
国立大学法人京都大学 |
用于预防和/或治疗肌萎缩性侧索硬化症的药剂
|
JP6695353B2
(ja)
|
2015-03-25 |
2020-05-20 |
ノバルティス アーゲー |
Fgfr4阻害剤としてのホルミル化n−複素環式誘導体
|
EP4234685A3
(en)
|
2015-04-17 |
2023-09-06 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
CN112625028A
(zh)
|
2015-06-19 |
2021-04-09 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
WO2016203404A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
CN105085398A
(zh)
*
|
2015-09-06 |
2015-11-25 |
合肥华方医药科技有限公司 |
一种博舒替尼异构体杂质的制备方法
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
DK3452465T3
(da)
|
2016-05-04 |
2021-02-08 |
Genoscience Pharma |
Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
|
ES2810852T3
(es)
|
2016-06-14 |
2021-03-09 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de shp2
|
US10253036B2
(en)
|
2016-09-08 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
EP3509423A4
(en)
|
2016-09-08 |
2020-05-13 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
KR20190051010A
(ko)
|
2016-09-08 |
2019-05-14 |
칼라 파마슈티컬스, 인크. |
치료 화합물의 결정형 및 그의 용도
|
AR110676A1
(es)
|
2016-10-07 |
2019-04-24 |
Novartis Ag |
Tratamiento del cáncer utilizando receptores de antígenos quiméricos
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
EP3592868B1
(en)
|
2017-03-06 |
2022-11-23 |
Novartis AG |
Methods of treatment of cancer with reduced ubb expression
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
CN110662762A
(zh)
|
2017-05-24 |
2020-01-07 |
诺华股份有限公司 |
抗体细胞因子移植蛋白和用于治疗癌症的方法
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
TW201912639A
(zh)
|
2017-09-11 |
2019-04-01 |
美商克魯松藥物公司 |
Shp2之八氫環戊烷并[c]吡咯別構抑制劑
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
EP4306111A3
(en)
|
2018-07-10 |
2024-04-17 |
Novartis AG |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
KR102643582B1
(ko)
|
2018-07-25 |
2024-03-05 |
어드밴스드 엑셀러레이터 어플리케이션즈 |
안정한 농축 방사성 핵종 복합체 용액
|
MX2021003158A
(es)
|
2018-09-18 |
2021-07-16 |
Nikang Therapeutics Inc |
Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2.
|
SG11202102981SA
(en)
|
2018-09-25 |
2021-04-29 |
Black Diamond Therapeutics Inc |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
EP3856349A1
(en)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
CN112867512A
(zh)
|
2018-09-25 |
2021-05-28 |
意大利国际先进加速器应用有限公司 |
联合疗法
|
CN112839715A
(zh)
|
2018-09-29 |
2021-05-25 |
诺华股份有限公司 |
抑制shp2活性化合物的制造方法
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
WO2020088631A1
(en)
|
2018-11-01 |
2020-05-07 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2020128612A2
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
KR20210129671A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
3-(1-옥소-5-(피페리딘-4-일)이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
EP4007592A1
(en)
|
2019-08-02 |
2022-06-08 |
LanthioPep B.V. |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
US20220298120A1
(en)
|
2019-08-15 |
2022-09-22 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
IL291996A
(en)
|
2019-11-01 |
2022-06-01 |
Syngenta Crop Protection Ag |
Fused heteroaromatic bicyclic compounds are active as pesticides
|
TW202134285A
(zh)
|
2019-11-26 |
2021-09-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
EP4077389A1
(en)
|
2019-12-20 |
2022-10-26 |
Novartis AG |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
IL298473A
(en)
|
2020-06-11 |
2023-01-01 |
Novartis Ag |
zbtb32 inhibitors and uses thereof
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
WO2022140472A1
(en)
|
2020-12-22 |
2022-06-30 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
WO2022152821A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
EP4323349A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
WO2022219407A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
AU2022258829A1
(en)
|
2021-04-16 |
2023-10-26 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
EP4359408A1
(en)
|
2021-06-24 |
2024-05-01 |
Syngenta Crop Protection AG |
2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
|
EP4370522A1
(en)
|
2021-07-14 |
2024-05-22 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
US20230303509A1
(en)
|
2022-03-28 |
2023-09-28 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023247360A1
(en)
|
2022-06-21 |
2023-12-28 |
Syngenta Crop Protection Ag |
Pesticidally active fused bicyclic heteroaromatic compounds
|
WO2024023666A1
(en)
|
2022-07-26 |
2024-02-01 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|
CN115286573A
(zh)
*
|
2022-08-04 |
2022-11-04 |
常州工程职业技术学院 |
一种1-烷氧基异喹啉化合物的绿色合成方法
|
WO2024102849A1
(en)
|
2022-11-11 |
2024-05-16 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|